§ 26-2D-3 — Definitions

As used in the Medical Psilocybin Act: A. "board" means the medical psilocybin advisory board; B. "clinician" means an approved health care provider licensed in New Mexico who holds a permit from the department to provide medical services to qualified patients; C. "department" means the department of health; D. "medical services" means services provided to a patient in an approved setting before, during and after the ingestion of psilocybin and includes a preparation session, an administration session and an integration session; E. "producer" means a person who has a permit from the department to grow and harvest or prepare psilocybin from psilocybin-producing mushrooms, including to compound, convert, process or manufacture psilocybin products directly or indirectly from psilocybin mushrooms and to package or repackage or label or relabel the products; F. "program" means the medical use of psilocybin program; G. "psilocybin" means the naturally occurring psychedelic compound 4- phosphoryloxy-N,N-dimethyltryptamine, also known as 4-PO-DMT, and its pharmacologically active metabolite psilocin, 4-hydroxy-N,N-dimethyltryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin; H. "qualified patient" means a patient whose clinician has judged the patient to be a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition; I. "qualifying condition" includes: (1) major treatment-resistant depression; (2) posttraumatic stress disorder; (3) substance use disorders; (4) end-of-life care; and (5) other conditions approved by the department; and J. "secretary" means the secretary of health.

Legislative History

Laws 2025, ch. 73, § 3.